Effect of High Protein Diet on Hepatic Steatosis, Inflammation and Mitochondrial Bioenergetics in Patients With MAFLD : A Randomized Controlled Trial
The clinical trial sponsored by the Institute of Liver and Biliary Sciences aims to investigate the effects of a high protein diet on hepatic steatosis and mitochondrial dysfunction in MAFLD patients, a condition increasingly prevalent in India. Given the rising incidence of MAFLD and the lack of established dietary guidelines, this study could provide pivotal data that may influence dietary recommendations and therapeutic strategies in metabolic diseases. The findings could position the sponsor as a leader in nutritional interventions for liver diseases, potentially opening avenues for partnerships with dietary supplement manufacturers and healthcare providers focused on metabolic health. The competitive landscape includes other dietary interventions, but this study's focus on high protein diets may differentiate it in the market.
Indication: Metabolic Dysfunction Associated Fatty Liver Disease
Modality: protein therapy
Target: Mitochondrial bioenergetics and metabolic parameters in patients with Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Sponsor: Institute of Liver and Biliary Sciences, India
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Mitochondrial bioenergetics and metabolic parameters in patients with Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
View original source fields
Condition raw: Metabolic Dysfunction Associated Fatty Liver Disease
Condition normalized: Metabolic Dysfunction Associated Fatty Liver Disease
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Mitochondrial bioenergetics and metabolic parameters in patients with Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Target normalized: Mitochondrial bioenergetics and metabolic parameters in patients with Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).